Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma

References

• Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159(4):1163-7; PMID:9507823; http://dx.doi.org/10.1016/S0022-5347(01)63541-9
   PubMed Web of Science ®Google Scholar
• Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173(1):48-51; PMID:15592023; http://dx.doi.org/10.1097/01.ju.0000148261.19532.2c
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4(5):385-90; PMID:12941198; http://dx.doi.org/10.1007/s11864-003-0039-2
   PubMedGoogle Scholar
• Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27(19):3225-34; PMID:19470934; http://dx.doi.org/10.1200/JCO.2008.19.9836
   PubMed Web of Science ®Google Scholar
• Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010; 16(5):1348-54; PMID:20179240; http://dx.doi.org/10.1158/1078-0432.CCR-09-2273
   PubMed Web of Science ®Google Scholar
• Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013; 24(2):343-9; PMID:23022995; http://dx.doi.org/10.1093/annonc/mds463
   PubMed Web of Science ®Google Scholar
• Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9(6):785-93; PMID:19496715; http://dx.doi.org/10.1586/era.09.43
   PubMed Web of Science ®Google Scholar
• Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013; 5(7); PMID:23818496; http://dx.doi.org/10.1101/cshperspect.a009209
   PubMed Web of Science ®Google Scholar
• Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013; 19(4):316-23; PMID:23867513; http://dx.doi.org/10.1097/PPO.0b013e31829e3c9a
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15(7):2207-14; PMID:19318488; http://dx.doi.org/10.1158/1078-0432.CCR-08-1306
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827):1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, Engelman JA. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011; 71(3):1081-91; PMID:21266357; http://dx.doi.org/10.1158/0008-5472.CAN-10-1623
   PubMed Web of Science ®Google Scholar
• Bezerra DP, Pessoa C, Moraes MO, Alencar NM, Mesquita RO, Lima MW, Alves AP, Pessoa OD, Chaves JH, Silveira ER, et al. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J Appl Toxicol 2008; 28(5):599-607; PMID:17975786; http://dx.doi.org/10.1002/jat.1311
   PubMed Web of Science ®Google Scholar
• Morikawa T, Matsuda H, Yamaguchi I, Pongpiriyadacha Y, Yoshikawa M. New amides and gastroprotective constituents from the fruit of Piper chaba. Planta Med 2004; 70(2):152-9; PMID:14994194; http://dx.doi.org/10.1055/s-2004-815493
   PubMed Web of Science ®Google Scholar
• Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther 2003; 99(1):1-13; PMID:12804695; http://dx.doi.org/10.1016/S0163-7258(03)00042-1
   PubMed Web of Science ®Google Scholar
• Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 2013; 73(1):23-30; PMID:22592999; http://dx.doi.org/10.1002/pros.22535
   PubMed Web of Science ®Google Scholar
• Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475(7355):231-4; PMID:21753854; http://dx.doi.org/10.1038/nature10167
   PubMed Web of Science ®Google Scholar
• Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-kappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2014; 74(2):177-86; PMID:24151226; http://dx.doi.org/10.1002/pros.22739
   PubMed Web of Science ®Google Scholar
• Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, Kolenko VM. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer 2014; 110(4):899-907; PMID:24434432
   PubMed Web of Science ®Google Scholar
• Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012; 11(7):1510-7; PMID:22532600; http://dx.doi.org/10.1158/1535-7163.MCT-11-0907
   PubMed Web of Science ®Google Scholar
• Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, Schreiber SL. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A 2012; 109(38):15115-20; PMID:22949699; http://dx.doi.org/10.1073/pnas.1212802109
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31(2):181-6; PMID:23213094; http://dx.doi.org/10.1200/JCO.2012.43.3383
   PubMed Web of Science ®Google Scholar
• Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011; 17(24):7754-64; PMID:21976535; http://dx.doi.org/10.1158/1078-0432.CCR-11-1002
   PubMed Web of Science ®Google Scholar
• Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, et al. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108(5):679-86; PMID:21156020
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012; 118(23):5894-902; PMID:22605650; http://dx.doi.org/10.1002/cncr.27582
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, Ramies DA, Morrissey S, Lee Y, Miles D, Holland JS, Dutcher JP. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 2012; suppl 5:abstr 364
   Google Scholar
• Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008; 7(12):1875-84; PMID:18981733; http://dx.doi.org/10.4161/cbt.7.12.7067
   PubMed Web of Science ®Google Scholar
• Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5:14; PMID:16689993; http://dx.doi.org/10.1186/1477-3163-5-14
   PubMedGoogle Scholar
• Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006; 312(5782):1882-3; PMID:16809515; http://dx.doi.org/10.1126/science.1130481
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res 2013; 73(14):4406-17; PMID:23674500; http://dx.doi.org/10.1158/0008-5472.CAN-12-4297
   PubMed Web of Science ®Google Scholar
• Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7(2):97-110; PMID:15158766; http://dx.doi.org/10.1016/j.drup.2004.01.004
   PubMed Web of Science ®Google Scholar
• Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007; 13(2 Pt 2):758s-63s; PMID:17255306; http://dx.doi.org/10.1158/1078-0432.CCR-06-1986
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Buonerba C, Biglietto M, Scognamiglio F, Chiurazzi B, Riccardi F, Carteni G. The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 2010; 36 Suppl 3:S16-20; PMID:21129605; http://dx.doi.org/10.1016/S0305-7372(10)70015-3
   PubMedGoogle Scholar
• Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009; 115(10 Suppl):2313-20; PMID:19402072; http://dx.doi.org/10.1002/cncr.24239
   PubMed Web of Science ®Google Scholar
• Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011; 6(3):214-21; PMID:21827395; http://dx.doi.org/10.2174/157488411797189433
   PubMedGoogle Scholar
• Morais C, Gobe G, Johnson DW, Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011; 43(11):1537-49; PMID:21854869; http://dx.doi.org/10.1016/j.biocel.2011.08.003
   PubMed Web of Science ®Google Scholar
• Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N, Murai M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24(3):377-84; PMID:12663495; http://dx.doi.org/10.1093/carcin/24.3.377
   PubMed Web of Science ®Google Scholar
• Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002; 99(1):53-7; PMID:11948491; http://dx.doi.org/10.1002/ijc.10303
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221(2):125-38; PMID:20225241; http://dx.doi.org/10.1002/path.2689
   PubMed Web of Science ®Google Scholar
• Kirsanov KI, Kotova E, Makhov P, Golovine K, Lesovaya EA, Kolenko VM, Yakubovskaya MG, Tulin AV. Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget 2014; 5(2):428-37; PMID:24504413
   PubMedGoogle Scholar
• Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM. Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res 2008; 14(17):5376-84; PMID:18765529; http://dx.doi.org/10.1158/1078-0432.CCR-08-0455
   PubMed Web of Science ®Google Scholar